Kalkine has a fully transformed New Avatar.

KALIN®

Kalkine Daily 22/06/2015 + Sonic Healthcare

Jun 21, 2015

In today’s daily we have covered stock research on Sonic Healthcare (Expensive).









 

The S&P 500 was down by 11.25 points or 0.53% to 2109.99 on Friday. U.S. stocks fell on Friday ahead of a summit next week that could decide whether Greece will need to print its own currency and ditch the euro. Euro zone leaders are scheduled to meet on Monday night in a last-ditch effort to reach a deal with Athens. As bank withdrawals across Greece ballooned to about 4.2 billion euros this week, the European Central Bank boosted its emergency funding for Greek banks.

ConAgra Foods' shares jumped 10.9 percent to $43.37 after activist hedge fund Jana Partnerstook a stake in the company. ConAgra's peer Pinnacle Foods   rallied 8.6 percent to $46.81 after earlier hitting a record high of $47.21. KB Home rose 9.4 percent to $16.37 after the homebuilder's quarterly results beat estimates. On Wednesday, markets await the final estimate of first quarter economic activity in the US. Economists expect GDP will be revised to show a 0.2 per cent contraction — in contrast to a 0.7 per cent decline previously reported — reflecting an improvement in personal consumption.



ConAgra Daily Chart (Source - Thomson Reuters)
 

S&P ASX 200 was up by 72.10 points or 1.30% on Friday and closed at 5597.00 points. The best performing sector for the week was the finance sector, which posted a 2.3 per cent weekly gain. Among the banks, ANZ was 1.2 per cent higher on the day and 3.3 per cent for the week.Commonwealth Bank rose 1.5 per cent for the day and 3.7 per cent for the week, National Australia Bank was up 1.6 per cent on the day and 4.3 per cent for the week, and Westpac lifted 1 per cent on the day and 3.5 per cent for the week.   BHP gained 1.6 per cent on Friday and 1.8 per cent for the week to close at $28.41 and Rio Tinto climbed 1.1 per cent on Friday - but slipped 2.8 per cent for the week - to close at $55.55.

Sydney Airport shares rose 2 per cent on Friday - but declined 1.5 per cent for the week - after the company said its total passenger traffic for May rose 1.6 per cent from a year earlier. Nickel producer Western Areas jumped 4.7 per cent on Friday and 1.3 per cent for the week after it announced the purchase of Glencore's Cosmos nickel complex in Western Australia in a $24 million deal. Western Areas said the acquisition would provide the company with additional exploration opportunities and a potential second mining operation alongside its Forrestania nickel operation in southern WA.




Sydney Airport Daily Chart (Source - Thomson Reuters)


Top Stocks ASX 200 - 19/06/2015


 


 

Get up to 2 Years of free subscription by inviting your friends to KALKINE!

For every friend of yours who joins KALKINE, we'll give you 3 months of free subscription (up to a limit of 24 months free subscription). If you recommend 3 friends and they join within a month of you referring them, you get 1 year free subscription to KALKINE reports added to your account (up to a limit of 24 months free subscription). Simply reply to this email with their name, e-mail and phone number.
 






 

Stock Of The Day - Sonic Healthcare (Expensive)

In today’s daily we cover Sonic Healthcare Limited  (SHL).  The company recently made an acquisition of a leading Swiss medical laboratory group Medisupport S.A for a mix of shares and cash. This is a logical step in the overall strategy of the company to strengthen its position in Europe. The acquisition will make SHL the number one player in the Swiss Laboratory market. Medisupport operates in 10 cities across Switzerland, employs 700 people, and has annual revenues of 160 million Swiss francs. The deal price represents a multiple of about 8 times Medisupport's 2015-16 earnings before interest, tax, depreciation and amortisation. Sonic said the deal is expected to boost earnings per share by 8 per cent initially and to drive further EPS increases after synergies have been realised.


Financial Highlights (Source - Company Reports) 

Sonic has a long history of successful acquisitions. The company has successfully executed and integrated 100 businesses till date. The company’s medical culture has served to attract like minded, high quality businesses each of which has provided incremental value and strength to the company. The company maintains a pipeline of synergistic opportunities at any point of time and maintains significant funding capacity to move forward with acquisitions at any point of time.  The company maintains a disciplined approach towards due diligence, compatibility and returns criterion ensuring it goes ahead with only a small percentage of acquisitions that it actually considers. 


The clinical Laboratory Process (Source - Company Reports)

Sonic is trying to place itself to benefit from a growing demand for diagnostic healthcare services. The company is a leading participant in pathology markets in Australia, Belgium, USA, Germany, Switzerland, UK and New Zealand. In Australia company also targets the diagnostic, imaging, medical centre and occupational health market. Part of company’s strategy is to maintain a global presence and consolidate its presence through acquisitions as well as organic growth and the latest acquisition of Medisupport is part of that strategy. An example of consolidation in an existing market through acquisitions is the Australian market where Sonic has a successful track record of consolidating a fragmented market of laboratories.  While the present focus of acquisitions is the current market, the company is likely to expand into new markets via acquisitions in the medium to long term. The company intends to maintain a conservative balance sheet while funding the acquisitions and always retains the key staff of the companies it acquires. 


Global Expansion (Source - Company Reports)

However the company itself admits that the conditions in many of the markets has been challenging and the company has not been able to register growth as per expectations. The company also has to put up with fee pressures in many of the markets. As a result of which company has to take many cost cutting initiatives. The long-term market growth rate in countries in which Sonic operates is around 5%. The market growth rate is supported by an ageing population, introduction of new tests and an increasing focus on preventive medication in the countries in which it operates. Acquisitions play a major role in registering the growth numbers. In last year’s annual report, the company mentioned that it experienced strong revenue growth in UK (12%), Switzerland (11%) and Germany 12% which were largely achieved due to acquisitions. Sometimes the growth in revenues comes at the cost of margins. For example a dilution of margin occurred when company acquired lower margin businesses in Germany. 


Sonic Healthcare Daily Chart (Source - Thomson Reuters)

Over the last five years the company has increased it’s net cash flow from operations from 429 million to 556 million. Over the same period the dividend paid per share has increased from 59 cents to 64 cents per share. These are not impressive growth numbers. The company’s revenue has increased from 2.9 billion in 2010 to 3.9 billion in 2014, which is an increase of approximately 34% in revenue over a period of five years. The company’s net profit after tax has increased from 293 million in 2010 to 384 billion in 2014, which is an increase of approximately 31% in net profit after tax over a period of five years. The company’s leverage ratio (defined as ratio of assets to equity) is a healthy 1.83 in 2014, while it was 1.92 in 2010. The company’s interest coverage ratio has ranged from 9.4 to 10.7 in the last five-year period, which implies that the company has significant unused debt capacity. 

The company is currently trading at a stock price of $21.62, which is somewhere close to the 52 week high of 21.380 and further from the 52 week low of 21.130. At the current price the company is trading at a Price to Earnings multiple of 22.88 and a dividend yield of 3.19%. There are other companies in the sector are trading at a similar P/E ratio and yield.
 
Given the less than stellar growth in revenues and profit achieved by company over a period of five years, we believe that the stock is expensive at the current price of $21.62.











 



 
 










 


Level 13  167 Macquarie Street
Sydney NSW 2000 Australia
E-Mail - [email protected]
Phone - 02 8667 3147


        
Note - You can also view this daily in the special reports section.

 


Disclaimer
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people.
Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376).
The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation.
Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product.
The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide.